News & Press Releases

25 May 2012

Oryzon nominates specific LSD1 inhibitor as drug candidate to enter preclinical development in Acute leukemia and other hematological cancers

8 May 2012

Oryzon to Present its LSD1 program in Acute Leukemias at the GTC’s 2nd Epigenetics in Drug Discovery conference in Boston

11 April 2012

Drugs from ORYZON shown to be efficacious in the treatment of Acute Leukemia

19 March 2012

Oryzon to attend BIO-Europe Spring 2012 Conference in Amsterdam

20 February 2012

Oryzon participates in a R&D European consortium in Parkinson’s disease

6 February 2012

Oryzon nominates bispecific LSD1/MAOB inhibitor as drug candidate to enter preclinical development in Huntington´s Disease

26 January 2012

Oryzon to Present at 4th CHI X-Gen Congress, Epigenetics, Targets and Therapies on March 6

15 September 2011

Oryzon will launch its first product onto the market

13 September 2011

ORYZON, PALO BIOPHARMA AND AROMICS awarded with funding for JOINT research program

7 July 2011

Oryzon on the official program of the Euromediag International Convention (EIC 2011)

News